Investigational drug · Phase 2
M5717
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Malaria Infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "M5717"
First trial start
2023
Nov 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "M5717", any sponsor or status.
Conditions studied
As listed on its trial records.
- Malaria Infection
Approved drugs for the same conditions: Malaria · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "M5717" as an intervention, largest first.
- Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)Pivotal-lookingCompleted
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
NCT05974267 · 192 participants · Start Nov 28, 2023 · Primary completion Dec 29, 2024
Drug: M5717 60 mg; Pyronaridine and 3 more · For: Malaria Infection
Sites: Ouagadougou, Burkina Faso; Kisumu, Kenya; Banjul, The Gambia · 4 sites in all
Merck KGaA, Darmstadt, GermanyIndustry
NCT03261401 · 88 participants · Start Sep 15, 2017 · Primary completion Jun 14, 2019
Drug: M5717; Placebo and 1 more · For: Healthy
Sites: Brisbane, Australia
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
NCT04250363 · 39 participants · Start Feb 17, 2020 · Primary completion Aug 18, 2021
Drug: PfSPZ Challenge; Palcebo and 9 more · For: Healthy
Sites: Leiden, Netherlands
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
NCT05689047 · 38 participants · Start Mar 29, 2023 · Primary completion May 28, 2024
Drug: M5717 330 mg; M5717 500 mg and 5 more · For: Acute Malaria
Sites: Nanoro, Burkina Faso; Ouagadougou, Burkina Faso; Lambaréné, Gabon · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Drug Interaction Studies of Cabamiquine:Ganaplacide Combination against Hepatic Plasmodium berghei.
Gal IR, Demarta-Gatsi C, Fontinha D, et al. · ACS Infect Dis 2025
- The delayed bloodstream clearance of Plasmodium falciparum parasites after M5717 treatment is attributable to the inability to modify their red blood cell hosts.
Parkyn Schneider M, Looker O, Rebelo M, et al. · Front Cell Infect Microbiol 2023
- Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models.
Yin X, Li Y, Bagchus W, et al. · Malar J 2023
- Kinetic Resolution of 2-Aryldihydroquinolines Using Lithiation - Synthesis of Chiral 1,2- and 1,4-Dihydroquinolines.
Yeo SH, Choi A, Greaves S, et al. · Chemistry 2023
- Translation of liver stage activity of M5717, a Plasmodium elongation factor 2 inhibitor: from bench to bedside.
Khandelwal A, Arez F, Alves PM, et al. · Malar J 2022
- An innovative study design with intermittent dosing to generate a GLP-regulatory package in preclinical species for long lasting molecule M5717, inhibitor of Plasmodium eukaryotic translation elongation factor 2.
Hewitt P, Abla N, Lignet F, et al. · Toxicol Appl Pharmacol 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.